Company Filing History:
Years Active: 2021
Title: Hye Ryeon Jeon: Innovator in Tissue Fibrosis Treatment
Introduction
Hye Ryeon Jeon is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the area of tissue fibrosis. His innovative work has the potential to improve treatment options for patients suffering from this condition.
Latest Patents
Hye Ryeon Jeon holds a patent for a recombinant protein aimed at preventing or treating tissue fibrosis. The patent, titled "Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same," describes a recombinant protein based on milk fat globule-EGF factor 8 (MFG-E8) protein. This protein includes the amino acid sequence of SEQ ID NO: 1. The invention demonstrates a significantly improved efficacy in preventing or treating tissue fibrosis compared to conventional MFG-E8 protein. The recombinant protein has the potential to restore tissue fibrosis levels to those very close to normal tissue.
Career Highlights
Hye Ryeon Jeon is associated with Nexel Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on addressing critical health issues.
Collaborations
He collaborates with esteemed colleagues, including Choong Seong Han and Dong Hun Woo, who contribute to his research endeavors.
Conclusion
Hye Ryeon Jeon's contributions to the field of tissue fibrosis treatment through his innovative patent highlight his role as a leading inventor in biomedical research. His work promises to enhance therapeutic options for patients and represents a significant advancement in medical science.